+908.9%
FTAI vs GSK
+47.2%
+861.7%
-52.1%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +3.3% | 0.0% | +3.3% | +3.3% |
| 7D | -5.2% | -3.5% | -1.7% | -4.4% |
| 30D | -17.9% | -3.4% | -14.5% | -17.2% |
| 3M | -22.7% | -8.1% | -14.6% | -21.3% |
| 6M | -28.0% | -11.1% | -16.9% | -26.0% |
| YTD | -5.0% | +0.7% | -5.7% | -5.1% |
| 1Y | +10.4% | +20.1% | -9.7% | +5.1% |
| 3Y | +425.2% | +46.1% | +379.1% | +367.8% |
| All | +908.9% | +47.2% | +861.7% | +809.8% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling